Top Markets
#1 GEKKO GEKKO +52.86%
#2 Helium Helium +48.09%
#3 Pons Pons +29.16%
#4 龙虾 (Lobster) 龙虾 (Lobster) +18.73%
#5 ADO Protocol ADO Protocol +18.06%
#6 Main Street Yield Main Street Yield +17.48%
#7 Collect on Fanable Collect on Fanable +16.65%
#8 OpenGradient OpenGradient +12.52%
#9 o1.exchange o1.exchange +12.13%
#10 Nillion Nillion +10.62%
Coin of the day
GEKKO GEKKO
設定
言語
日本
通貨
USD
テーマ
Corvus Pharmaceuticals, Inc. Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc.

CRVS
株式のランク #8729
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
株価
$14.07
最終同期: 2026-08-28
時価総額
$1.18B
変化（1日）
-4.41%
変化（1年）
145.13%
国
US
取引 Corvus Pharmaceuticals, Inc. (CRVS)

カテゴリー

Healthcare
Corvus Pharmaceuticals, Inc.（CRVS）の株価履歴
終値の最高値: $14.55 （2026-08-01）

終値の最安値: $14.35 （2016-03-01）
Corvus Pharmaceuticals, Inc. の株価履歴（2016 ～ 2026）
年間株価パフォーマンス
年 パフォーマンス
2026 (TTM) 52.04%
2025 20.69%
2024 304.94%
2023 86.02%
2022 -68.55%
2021 -28.60%
2020 -6.17%
2019 -13.67%
2018 -53.58%
2017 -32.68%
2016 0.00%
類似企業または競合の株価
企業 株価 変化率 1年% 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $542.09 38.63%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.03K 44.13%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.53 -12.70%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $138.18 473.58%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $759.27 7.20%
CH